(19)
(11) EP 4 248 957 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
29.11.2023 Bulletin 2023/48

(43) Date of publication:
27.09.2023 Bulletin 2023/39

(21) Application number: 22828609.2

(22) Date of filing: 13.05.2022
(51) International Patent Classification (IPC): 
A61K 31/12(2006.01)
A61K 45/06(2006.01)
A23L 33/10(2016.01)
 A61K 31/444(2006.01)
A61P 1/16(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/444; A23L 33/10; A61K 31/12; A61K 45/06; A61P 1/16; A23L 33/105
(86) International application number:
PCT/KR2022/006873
(87) International publication number:
WO 2022/270760 (29.12.2022 Gazette 2022/52)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 24.06.2021 KR 20210082417
22.11.2021 KR 20210160931

(71) Applicant: University Industry Foundation, Yonsei University Wonju Campus
Gangwon-do 26493 (KR)

(72) Inventors:
  • CHUNG, Choon Hee
    Wonju-si Gangwon-do 26438 (KR)
  • LEE, Eun Soo
    Wonju-si Gangwon-do 26448 (KR)
  • HA, Kyung Bong
    Wonju-si Gangwon-do 26385 (KR)
  • LEE, Dong Keon
    Chuncheon-si Gangwon-do 24420 (KR)
  • PARK, Na Won
    Wonju-si Gangwon-do 26493 (KR)
  • JO, Su Ho
    Wonju-si Gangwon-do 26493 (KR)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstraße 3
81675 München
81675 München (DE)

   


(54) METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-BETA RECEPTOR INHIBITOR


(57) The present invention relates to a pharmaceutical composition, quasi-drug, and food composition for preventing, ameliorating, or treating steatohepatitis, comprising a curcumin derivative and a TGF-β receptor inhibitor as active ingredients. In the composition, the TGF-β receptor inhibitor inhibits fibrosis of liver tissues, the curcumin derivative inhibits adipogenesis of hepatocyte increased during fibrosis inhibition process. Thus, compared to when a curcumin derivative or a TGF-β receptor inhibitor is administered alone as in the conventional cases, the composition exhibits an excellent effect of preventing and treating steatohepatitis, and therefore, can be used as a pharmaceutical composition, quasi-drug, and food composition for preventing, ameliorating, or treating metabolic liver diseases, including steatohepatitis.